Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
The management of CNS lymphomas is poised for another revolution due to the emergence of therapeutic monoclonal antibodies. As the technology for generating monoclonal antibodies matures and obstacles are solved, therapeutic monoclonal antibodies will play an increasing role in the management of cancer. This article will review the biology of CNS lymphomas, monoclonal antibody technology, limitation of existing chemotherapies and the application of therapeutic monoclonal antibodies for the treatment of CNS lymphomas.
Wong
Eric T
ET
Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. ewong@bidmc.harvard.edu
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000074301:CD52 Antigen; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology; D019151:Peptide Library; D000069283:Rituximab; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D019151:Peptide Library; D051918:Sialic Acid Binding Ig-like Lectin 2; C448700:epratuzumab; D000074323:Alemtuzumab; D000069283:Rituximab